key: cord-0961829-e7ns91zu
authors: Hamada, S.; Tanabe, N.; Inoue, H.; Hirai, T.
title: Wearing of medical mask over the high-flow nasal cannula for safer oxygen therapy in the COVID-19 era
date: 2020-11-16
journal: Pulmonology
DOI: 10.1016/j.pulmoe.2020.10.009
sha: 29973eb107b1dd1375b5f93f8b3bad00c26de089
doc_id: 961829
cord_uid: e7ns91zu

nan

The emergence of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and its associated respiratory disease, coronavirus disease 2019 (COVID-19), has imposed social and medical burdens worldwide. Up to 12% of patients with SARS-CoV-2 infection required intensive care unit admission. Among them, 6070% had acute hypoxic respiratory failure. 1 High-flow nasal cannula (HFNC) oxygen therapy is the generally prescribed respiratory therapy for acute hypoxic respiratory failure. This therapy might help limit the need for invasive mechanical ventilation (IMV) and prevent the occurrence of associated adverse events such as ventilator-associated pneumonia in COVID-19 patients. 2 However, administration of HFNC oxygen therapy in COVID-19 patients remains controversial, owing to uncertainties regarding the potential risk of viral transmission to healthcare workers, as this therapy is considered as an aerosol-generating procedure. 3 medical mask over the HFNC device to limit particle dispersion due to exhaled gas flow. 4, 5 These recommendations are partially supported by two previous experimental studies that indirectly examined exhaled breath by visualizing airflow movement using smoke 6 and computational fluid dynamic (CFD) simulation. 7 However, to the best of our knowledge, there is no direct evidence that this strategy could reduce the risk of SARS-CoV-2 transmission to healthcare workers in clinical settings due to the technical difficulty in direct visualization of particle dispersion. Here we present an experimental trial with a novel fine particle visualization system, which allowed evaluating whether particle dispersion from coughing while on HFNC oxygen could be suppressed by an appropriately placed medical mask.

We ran four scenarios with a healthy volunteer with nasal cannula at 3 L/min and This report substantially increases our understanding on the droplet dispersion risk during HFNC therapy. Wearing a medical mask over HFNC device almost completely suppressed particle dispersion induced by coughing. Our findings are first direct evidence that wearing a medical mask will be a useful manner in administering HFNC oxygen therapy and strongly support the recommendation as described above. Moreover, the present direct visualization of the suppressive effect of the medical mask in vivo further The visual evidence presented here should be shared with all care-givers wearing personal protective equipment to encourage the use of HFNC oxygen therapy for managing hypoxic COVID-19 patients. Hopefully, this method helps overcome this disastrous pandemic situation worldwide. 

Intensive care management of coronavirus disease 2019 (COVID-19): Challenges and recommendations

High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: Systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission

Consensus statement: Safe airway society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group

Respiratory care committee of Chinese Thoracic Society [Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia

Protecting healthcare workers from SARS-CoV-2 infection: practical indications

Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks

Preliminary findings on control of dispersion of aerosols and droplets during high-velocity nasal insufflation therapy using a simple surgical mask: Implications for the high-flow nasal cannula